Current role of ceftobiprole in the treatment of hospital-acquired and community-acquired pneumonia: expert opinion based on literature and real-life experiences.
Ivan Gentile, Simone Giuliano, Silvia Corcione, Francesco Giuseppe De Rosa, Marco Falcone, Daniele Roberto Giacobbe, Alberto Enrico Maraolo, Claudio Maria Mastroianni, Alessandra Oliva, Renato Pascale, Carlo Tascini, Giusy Tiseo, Pierluigi Viale, Matteo Bassetti
Author Information
Ivan Gentile: Section of Infectious Diseases, Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy.
Simone Giuliano: Infectious Diseases Clinic, Azienda Sanitaria Universitaria del Friuli Centrale (ASUFC), Udine, Italy.
Silvia Corcione: Infectious Diseases Unit, Department of Medical Sciences, University of Torino, Torino, Italy.
Francesco Giuseppe De Rosa: Department of Medical Sciences, University of Turin, Turin, Italy.
Marco Falcone: Infectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Daniele Roberto Giacobbe: Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.
Alberto Enrico Maraolo: Section of Infectious Diseases, Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy.
Claudio Maria Mastroianni: Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Alessandra Oliva: Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy. ORCID
Renato Pascale: Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
Carlo Tascini: Infectious Diseases Clinic, Azienda Sanitaria Universitaria del Friuli Centrale (ASUFC), Udine, Italy.
Giusy Tiseo: Infectious Diseases Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliera Universitaria Pisana, University of Pisa, Pisa, Italy.
Pierluigi Viale: Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
Matteo Bassetti: Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.
INTRODUCTION: Community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP) are major global health challenges, with high morbidity and mortality rates. The increasing prevalence of multidrug-resistant (MDR) bacteria may diminish the effectiveness of standard empirical antibiotics, highlighting the need for broader-spectrum agents that target also MDR organisms. AREAS COVERED: This review summarizes findings from a PubMed search on the use of ceftobiprole in CAP and HAP. It highlights key features of ceftobiprole, including its mechanism of action and broad spectrum of activity against multiple MDR pathogens. Clinical data from randomized controlled trials and real-world studies underscore its non-inferiority to standard treatments, with favorable safety profile and high clinical cure rates even in challenging cases. EXPERT OPINION: Ceftobiprole represents a valid option for the patients with CAP and HAP. Its main advantages include its broad spectrum of activity, making it a valuable therapeutic choice for treating polymicrobial infections, and its favorable safety profile, which makes it a good candidate in elderly patients with multiple comorbidities and polypharmacy. Caution is advised in patients at high risk of ESBL-producing organisms or MDR infections, where combination therapy is recommended. Moreover, therapeutic drug monitoring is recommended to improve outcomes, particularly in complex clinical conditions.
